Medico ricercatore Onco-Pulmonology
📍 Azienda Ospedaliero-Universitaria Pisana — Pulmonary Unit
Bourse reçue: €3.000Analisi real-world dell'incidenza di polmonite indotta da inibitori del checkpoint immunitario (CIP) in pazienti con tumore al polmone trattati con immunoterapia. Coorte retrospettiva di 10 anni presso AOU Pisana (~1.000 pazienti). I trial registrano CIP rate 2,7-4,1%, il real-world dice 10-19%: il 20% steroid-refractory con alta mortalità.
To generate real-world epidemiological evidence on the incidence, clinical-radiological phenotypes, and risk factors of checkpoint inhibitor–related pneumonitis (CIP) in lung cancer patients, bridging the gap between trial data and practice. The study will provide insights on CIP incidence and multidimensional characteristics, potentially informing future research and refinement of diagnostic and…
Comprehensive characterization of real-world CIP epidemiology in a 10-year lung cancer cohort, including accurate incidence rates by ICI class, identified risk factors, multidimensional clinical phenotypes, and outcome patterns. Dissemination of findings through peer-reviewed publications and intern…
Chaque 3 000 € collectés = un grant de plus pour le prochain appel. Vous courez, vous donnez, ils font de la recherche.
Faire un don Voir l'appel ouvert